Three things to know:
1. Dexycu is an FDA-approved single intraocular dose for the treatment of postoperative inflammation.
2. EyePoint’s new agreement will make Dexycu available to the system’s 8.5 million patients, opening new distribution channels in California, Washington, Georgia, Colorado and mid-Atlantic states.
3. The system also granted EyePoint preferred vendor status.
“We continue to receive strong reception and increasing adoption of this innovative product from physicians and [ASCs] across the U.S.,” EyePoint President and CEO Nancy Lurker said in a press release. “Dexycu has the potential to replace the burdensome post-cataract surgery steroid regimen by providing an easy-to-administer, extended release treatment option with a favorable safety profile.”
More articles on supply chain:
How ASCs can improve infection control and meet CMS accreditation standards: 3 experts weigh in
Surgical analytics provider inks 1st major contract under Dr. Robert Lazzara
Asian PE firm to buy Isreali devicemaker for $1B+ — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.